Brian G Lee, MD | |
110 Irving St Nw, Rm 4b42, Washington, DC 20010-2976 | |
(202) 877-7259 | |
(202) 877-7258 |
Full Name | Brian G Lee |
---|---|
Gender | Male |
Speciality | Critical Care (intensivists) |
Experience | 30 Years |
Location | 110 Irving St Nw, Washington, District Of Columbia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487635512 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0200X | Internal Medicine - Critical Care Medicine | MD33686 (District Of Columbia) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Medstar Washington Hospital Center | Washington, DC | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Medstar Medical Group Ii Llc | 0547413825 | 1776 |
Medstar Medical Group Ii Llc | 0547413825 | 1776 |
News Archive
C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is a risk factor for stroke. Studies have report a higher C677T homozygosity frequency in Chinese than in Europeans. Usually, the detection of genetic diseases is rather complicated on a large scale owing to the invasive sampling and a cumbersome DNA extraction process.
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
For many years, the answer to that question was unequivocally "No." But as the University of Utah School of Medicine's annual Utah Cardiac Recovery Symposium will explore on Jan. 12-13, advances in treating heart failure are giving physicians, surgeons and researchers reason to hope the deadly disease might one day be defeated.
Boston Medical Center was awarded a multi-million dollar grant from the National Institutes of Health to improve function for chronic lower back pain (cLBP) using a non-pharmacologic approach.
› Verified 5 days ago
Entity Name | Whc Physician Group Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1700154226 PECOS PAC ID: 6103093513 Enrollment ID: O20120125000252 |
News Archive
C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is a risk factor for stroke. Studies have report a higher C677T homozygosity frequency in Chinese than in Europeans. Usually, the detection of genetic diseases is rather complicated on a large scale owing to the invasive sampling and a cumbersome DNA extraction process.
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
For many years, the answer to that question was unequivocally "No." But as the University of Utah School of Medicine's annual Utah Cardiac Recovery Symposium will explore on Jan. 12-13, advances in treating heart failure are giving physicians, surgeons and researchers reason to hope the deadly disease might one day be defeated.
Boston Medical Center was awarded a multi-million dollar grant from the National Institutes of Health to improve function for chronic lower back pain (cLBP) using a non-pharmacologic approach.
› Verified 5 days ago
Entity Name | Medstar Medical Group Ii Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000415 |
News Archive
C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is a risk factor for stroke. Studies have report a higher C677T homozygosity frequency in Chinese than in Europeans. Usually, the detection of genetic diseases is rather complicated on a large scale owing to the invasive sampling and a cumbersome DNA extraction process.
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
For many years, the answer to that question was unequivocally "No." But as the University of Utah School of Medicine's annual Utah Cardiac Recovery Symposium will explore on Jan. 12-13, advances in treating heart failure are giving physicians, surgeons and researchers reason to hope the deadly disease might one day be defeated.
Boston Medical Center was awarded a multi-million dollar grant from the National Institutes of Health to improve function for chronic lower back pain (cLBP) using a non-pharmacologic approach.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Brian G Lee, MD 1201 Seven Locks Rd, Suite 200, Rockville, MD 20854-2931 Ph: (301) 652-5771 | Brian G Lee, MD 110 Irving St Nw, Rm 4b42, Washington, DC 20010-2976 Ph: (202) 877-7259 |
News Archive
C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is a risk factor for stroke. Studies have report a higher C677T homozygosity frequency in Chinese than in Europeans. Usually, the detection of genetic diseases is rather complicated on a large scale owing to the invasive sampling and a cumbersome DNA extraction process.
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
For many years, the answer to that question was unequivocally "No." But as the University of Utah School of Medicine's annual Utah Cardiac Recovery Symposium will explore on Jan. 12-13, advances in treating heart failure are giving physicians, surgeons and researchers reason to hope the deadly disease might one day be defeated.
Boston Medical Center was awarded a multi-million dollar grant from the National Institutes of Health to improve function for chronic lower back pain (cLBP) using a non-pharmacologic approach.
› Verified 5 days ago
Dr. Adefolaju Oketokun, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1629 K Street Nw, Suite 300, Washington, DC 20006 Phone: 202-636-1360 Fax: 202-636-5137 | |
Dr. Uzoamaka Theodora Nwaogwugwu, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2041 Georgia Avenue Nw, Washington, DC 20060 Phone: 202-865-7677 | |
Ms. Sruthi Nukalapati Reddy, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Road Nw, 6 Phc, Washington, DC 20007 Phone: 202-444-8123 | |
Dr. Kaustubh Subhash Yadwadkar, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Cg201, Washington, DC 20007 Phone: 304-206-7595 | |
Dr. Monica Vohra, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1525 7th St Nw, Washington, DC 20001 Phone: 202-386-7020 Fax: 202-265-1970 | |
Anteneh A Tesfaye, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw Ste C2151, Washington, DC 20010 Phone: 202-877-6998 Fax: 202-877-8909 | |
Erica Nakajima, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 5255 Loughboro Rd Nw Fl 1, Washington, DC 20016 Phone: 202-660-6500 |